EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Uncovering stage‐specific neural and molecular progression in Alzheimer's disease: Implications for early screening

Yun Lin, Xue Shi, Jia Mu, Huixia Ren, Xiaosen Jiang, Lin Zhu, Xingya Cai, Chongyuan Lian, Zian Pei, Yongfang Zhang, Cong Wang, Guixue Hou und 9 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Yun Lin und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Intelligent Medical Research (IIMR), BGI Genomics, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Ministry of Science and Technology of China, National Key R&D Program of China, Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Understanding molecular, neuroanatomical, and neurophysiological changes in cognitive decline is crucial for comprehending Alzheimer's disease (AD) progression and facilitating objective staging and early screening. METHODS We enrolled 277 participants and employed a multimodal approach, integrating genomics, metagenomics, metabolomics, magnetic resonance imaging (MRI), and electroencephalogram (EEG) to investigate the AD continuum, from subjective cognitive decline (SCD) through mild cognitive impairment (MCI) to advanced AD. RESULTS Key markers and mechanisms were identified for each stage: initial neurophysiological deficits in SCD with compensatory metabolomic responses, gut‐brain axis dysregulation in MCI, and extensive metabolic disruption and multisystem breakdown in AD. Using random forest models, we identified specific feature combinations that achieved predictive areas under the curve (AUCs) of 0.78 for SCD, 0.84 for MCI, and 0.98 for AD, highlighting EEG as a particularly effective early screening tool. DISCUSSION This study elucidates AD's pathophysiological progression and highlights the potential of machine learning‐assisted multimodal strategies for early detection and staging. Highlights Early electroencephalogram (EEG) changes and compensatory metabolomic responses define subjective cognitive decline (SCD) stage. In mild cognitive impairment (MCI), gut–brain axis dysfunction alters microbial diversity and functional pathways. In Alzheimer's disease (AD), systemic breakdown disruption enables near‐perfect machine learning (ML) detection. Random forest models yield predictive areas under the curve (AUCs) of 0.78 (SCD), 0.84 (MCI), 0.98 (AD). EEG is a convenient, cost‐efficient marker for early screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansDisease ProgressionMaleFemaleAgedEarly DiagnosisMagnetic Resonance ImagingElectroencephalographyMetabolomicsBrainMachine LearningBiomarkersAged, 80 and over

Stichwörter der Autor:innen

Alzheimer's disease (AD)EEGMRIgut microbiotamachine learningmetabolomicsmild cognitive impairment (MCI)multi‐omicsneuroimagingsubjective cognitive decline (SCD)

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Institute of Intelligent Medical Research (IIMR), BGI Genomics, Shenzhen, Guangdong, China.
  • Department of Neurology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China.
  • Department of Geriatrics, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China.
  • BGI Research, Shenzhen, Guangdong, China.
  • Shenzhen Bay Laboratory, Gaoke Innovation Center, Shenzhen, Guangdong, China.
  • Department of Electronic and Electrical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, China.

Förderung

  • the Ministry of Science and Technology of China
  • National Key R&D Program of China
  • Natural Science Foundation of China
  • Research Program of Central Health Commission
  • Special Foundation for Shenzhen Basic Research Program
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Lin, Y., Shi, X., Mu, J., Ren, H., Jiang, X., Zhu, L., Cai, X., Lian, C., Pei, Z., Zhang, Y., Wang, C., Hou, G., Lin, L., Nie, C., Song, C., Gao, S., Zhao, L., Wang, J., Jiang, X., …, & Guo, Y. (2025). Uncovering stage‐specific neural and molecular progression in Alzheimer's disease: Implications for early screening. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70182

Vancouver

Lin Y, Shi X, Mu J, Ren H, Jiang X, Zhu L, et al. Uncovering stage‐specific neural and molecular progression in Alzheimer's disease: Implications for early screening. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70182

BibTeX
@article{Lin2025,
  author = {Lin, Yun and Shi, Xue and Mu, Jia and Ren, Huixia and Jiang, Xiaosen and Zhu, Lin and Cai, Xingya and Lian, Chongyuan and Pei, Zian and Zhang, Yongfang and Wang, Cong and Hou, Guixue and Lin, Liang and Nie, Chao and Song, Cai and Gao, Shuyang and Zhao, Lijian and Wang, Jian and Jiang, Xin and Wang, Jing and Guo, Yi},
  title = {Uncovering stage‐specific neural and molecular progression in Alzheimer's disease: Implications for early screening},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70182}
}
Kostenlos starten →